

TZIELD (TEPLIZUMAB) INFUSION ORDERS

P: 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION: Fax completed for	m, insurance information, and clinical documentation to 855.889.2946
Patient Name:	DOB: Phone:
Patient Status: ☐ New to Therapy ☐ Continuing Th	erapy Next Treatment Date:
MEDICAL INFORMATION	
Diagnosis: ☐ Type 1 diabetes mellitus with unspecifi	ed complications (ICD-10: E10.8)
☐ Type 1 diabetes mellitus without comp	olications (ICD-10: E10.9)
☐ Other: ICD-10 code:	
Patient Weight: lbs. (required) Patient	Height: inches (required)
Allergies:	
THERAPY ORDER	
☐ Infuse Tzield IV daily for 14 days according to the foll	owing dosing regimen:
	cg/m ² • Day 5 through 14: 1,030 mcg/m ²
• Day 2: 125 mcg/m ² • Day 4: 500 m	
Patients should be pre-medicated with APAP or NSAI. Pre-medication orders :	D, antihistamine, and/or an anti-emetic for 1st 5 doses
☐ Acetaminophen mg PO ☐ Ibuprofen	ma PO Toradol 30ma IV
☐ Diphenhydramine 25 mg PO ☐ Cetirizine 10i	
☐ Zofran mg IV ☐ Cetirizine 10	
Administer pre-meds for: ☐ First 5 doses only ☐	Prior to all doses U Other:
Lab orders: ☐ Baseline CBC & LFTs (required) Baseline hold parameters: Lymphocyte count <1,0 ANC <1500/mcl ALT/	00/mcL, Hgb <10g/dL, Platelets <150,000/mcL, AST > 2x ULN, or bilirubin > 1.5x ULN
Repeat CBC & LFTs every day(s)	
Notify physican for abnormal labs.	
Discontinue treatment for AST/ALT > 5x ULN or bilirubin > 3x ULN Discontinue treatment for prolonged lymphopenia (<500/mcL) lasting 1 week or longer	
Required labs to be drawn by: Paragon Reference Reference Paragon Reference Reference Paragon Reference Paragon Paragon Reference Paragon Paragon	
Other orders:	
Home biologic IV Ana-kit (adult), dispense per protoc	
EpiPen 0.3mg IM (2-pack) or compounded syri	
 Diphenhydramine 50mg IV and PO 	
Normal Saline 1000mL	
PROVIDER INFORMATION	
agent in dealing with medical and prescription insurance companies, and to select the pre-	c. and its employees to serve as your prior authorization and specialty pharmacy designated ferred site of care for the patient.
Provider NDI: Signa Phone:	ture: Date: Fax: Contact Person:
□ Opt out of Paragon selecting site of care (if checke	d, please list site of care):
PREFERRED LOCATION	
	9,00
City: State:	View our locations here:



COMPREHENSIVE SUPPORT FOR TZIELD THERAPY

PATIENT INFORMATION:	
Patient Name: DOB:	
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL	
☐ Include signed and completed order (MD/prescriber to complete page 1)	
☐ Include patient demographic information and insurance information	
☐ Include patient's medication list	
☐ Supporting clinical notes (H&P) to support primary diagnosis - Including:	
\square Does the patient have a at least two positive pancreatic islet cell autoantibodies?	
☐ Yes ☐ No If yes, please indicate:	
\square Does the patient have dysglycemia without overt hyperglycemia? \square Yes \square No	
☐ Patient does not have a clinical history to suggest type 2 diabetes	
\square Patient does not have an acute infection with Epstein-Barr Virus or Cytomegalovirus	
☐ Supporting labs/tests	
☐ Oral glucose tolerance test (if available)	
☐ Lab results indicating pancreatic islet cell autoantibodies	
Other medical necessity:	
REQUIRED PRE-SCREENING	
☐ Baseline CBC & LFTs - attach results	
☐ Pancreatic islet cell autoantibodies	
☐ Documentation of dysglycemia without overt hyperglycemia	

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance